Dear Editor,
Arsenic trioxide (ATO), as a single agent, is most commonly used at present in cases of relapsed acute promyelocytic leukemia (APL) for induction of remission. It has been shown that it is equally effective in newly diagnosed cases of APL, with much less toxicity [1]. Therefore, for the elderly APL patients, especially for those truly frail patients who are considered unfit for chemotherapy, ATO could be a reasonable alternative to the current standard approach. Hepatitis B virus (HBV) reactivation in hepatitis B surface antigen (HBsAg)-negative patients is a well-known complication of lymphoma treatment in the rituximab era [2]. To our knowledge, this is the first case of HBV reactivation in an APL patient treated with ATO.
A 62-year-old man with diabetes who presented with epistaxis and general malaise was admitted to our hospital. He was given a diagnosis of APL and was immediately treated with induction therapy consisting of idarubicin, cytarabine, and all-trans retinoic acid. He achieved complete hematology and molecular remission after the first course of induction therapy. After consolidation therapy with mitoxantrone and cytarabine, he developed acute lung injury and acute respiratory distress syndrome following severe infection. Therefore, he was given single-agent ATO intravenously (0.15 mg kg−1 day−1, 5 days/week for 5 weeks), as this was considered to be less toxic than conventional chemotherapy. Treatment was interrupted in the first week of therapy because he developed hematologic toxicities including neutropenia (grades 3 to 4). ATO was carefully resumed, and no further severe complications occurred. As this patient had prior resolved HBV infection, negative for HBsAg but positive for antibody to hepatitis B core antigen (anti-HBc) and antibody to HbsAg (anti-HBs), HBV DNA surveillance was regularly performed before initiating the second treatment course. Quantitative PCR assay for serum HBV DNA indicated 4.0 log copy/mL (normal range, <2.1 log copy/mL), and HBsAg and anti-HBs were converted to positive and negative, respectively. Anti-HBc remained positive, but no significant elevations in serum transaminases were observed. HBV reactivation was diagnosed. The patient was immediately given antiviral therapy consisting of entecavir 0.5 mg day−1 orally. Serum HBV DNA values became negative 3 weeks after this treatment. He completed a second course of ATO treatment without developing hepatotoxicity under the preventive treatment of entecavir. Two weeks after the treatment, he experienced varicella zoster virus (VZV) reactivation, which was treated with oral valaciclovir. The characteristic clinical feature was resolved without subsequent complications like postherpetic neuralgia. The patient then received all-trans retinoic acid as a maintenance therapy, and he maintains complete molecular remission.
Despite arsenic is well-known as a toxic agent, as a therapeutic entity, ATO has been generally well tolerated. Common potentially serious toxicities include APL differentiation syndrome and electrocardiogram abnormalities. Although no significant hepatotoxicity was reported, the overall hepatotoxicity was observed in approximately 35 % of patients in the Iranian and Indian studies, which were administered with single-agent ATO for the frontline therapy of APL [1, 3]. The underlying mechanism of HBV reactivation during chemotherapy has remained unclear. The promyelocytic leukemia (PML) protein critically regulates several cellular functions that oppose tumorigenesis such as oncogene-induced senescence, apoptosis, and the response to DNA damage and to viral infections. Its associated PML nuclear bodies (PML NBs) have been implicated in host immune response to viral infection [4]. Several viral proteins in herpes viruses and HBV interact with PML and PML NBs [5, 6]. ATO was shown to induce the degradation of PML as a direct target of ATO by the SUMOylation [7]. ATO possibly affects HBV and herpes virus reactivation by degradation of PML. Indeed, a previous report [8] showed that VZV reactivation is a common complication of ATO treatment. Thus, clinicians should be aware of possible HBV reactivation when patients with resolved HBV infection are treated with regimens containing arsenic compounds, especially in HBV endemic areas.
References
Mathews V, George B, Chendamarai E, Lakshmi KM, Desire S, Balasubramanian P, Viswabandya A, Thirugnanam R, Abraham A, Shaji RV, Srivastava A, Chandy M (2010) Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data. J Clin Oncol 28:3866–3871
Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, Chan HL, Hui EP, Lei KI, Mok TS, Chan PK (2009) Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 27:605–611
Ghavamzadeh A, Alimoghaddam K, Rostami S, Ghaffari SH, Jahani M, Iravani M, Mousavi SA, Bahar B, Jalili M (2011) Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia. J Clin Oncol 29:2753–2757
Bernardi R, Pandolfi PP (2007) Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. Nat Rev Mol Cell Biol 8:1006–1016
Sides MD, Block GJ, Shan B, Esteves KC, Lin Z, Flemington EK, Lasky JA (2011) Arsenic mediated disruption of promyelocytic leukemia protein nuclear bodies induces ganciclovir susceptibility in Epstein-Barr positive epithelial cells. Virology 416:86–97
Chung YL, Tsai TY (2009) Promyelocytic leukemia nuclear bodies link the DNA damage repair pathway with hepatitis B virus replication: implications for hepatitis B virus exacerbation during chemotherapy and radiotherapy. Mol Cancer Res 7:1672–1685
Zhang XW, Yan XJ, Zhou ZR, Yang FF, Wu ZY, Sun HB, Liang WX, Song AX, Lallemand-Breitenbach V, Jeanne M, Zhang QY, Yang HY, Huang QH, Zhou GB, Tong JH, Zhang Y, Wu JH, Hu HY, de The H, Chen SJ, Chen Z (2010) Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science 328:240–243
Au WY, Kwong YL (2005) Frequent varicella zoster reactivation associated with therapeutic use of arsenic trioxide: portents of an old scourge. J Am Acad Dermatol 53:890–892
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yujiri, T., Tanaka, M., Taguchi, A. et al. Reactivation of hepatitis B virus in a hepatitis B surface antigen-negative patient with acute promyelocytic leukemia treated with arsenic trioxide. Ann Hematol 93, 351–352 (2014). https://doi.org/10.1007/s00277-013-1804-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-013-1804-3